ArticleBMC gastroenterology2026
Development and validation of a nomogram to predict recurrence after hepatectomy in overweight patients with hepatocellular carcinoma: a retrospective cohort study.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundEven after curative hepatectomy, postoperative recurrence remains a major challenge for patients with hepatocellular carcinoma (HCC). Body mass index (BMI) has been associated with the risk of HCC development; however, the prognostic impact of high BMI on postoperative recurrence in patients with HCC has not been fully elucidated.
objectiveTo evaluate the risk factors associated with postoperative recurrence in overweight HCC patients with negative surgical margins and to develop a prognostic nomogram for recurrence prediction.
methodsThis single-center retrospective study included 259 overweight patients (BMI ≥ 24 kg/m²) who underwent curative hepatectomy for pathologically confirmed HCC with negative margins. Patients were randomly divided into a training cohort and a validation cohort at a 7:3 ratio. Univariate and multivariate Cox regression analyses were performed to identify independent risk factors associated with recurrence-free survival (RFS), incorporating clinical, laboratory, and pathological variables. A prognostic nomogram was constructed to estimate the 1-, 2-, and 3-year recurrence probabilities. Kaplan-Meier and log-rank tests were used to compare RFS between the high- and low-risk groups.
resultsUnivariate Cox analysis identified poor preoperative Eastern Cooperative Oncology Group (ECOG) performance status (PS score), high nutrition risk screening (NRS 2002) score, advanced AJCC 8th stage, presence of satellite nodules, vascular invasion, elevated alkaline phosphatase (ALP), and a high platelet-to-lymphocyte ratio (PLR) as risk factors for RFS, whereas prolonged activated partial thromboplastin time (APTT) was a protective factor (all P < .05). Multivariate Cox regression revealed that PS score and NRS 2002 were independent predictors of RFS. In the training cohort, the nomogram demonstrated favorable discrimination, with a concordance index (C-index) of 0.724, and the areas under the ROC curve for predicting 1-, 2-, and 3-year RFS were 0.728, 0.769, and 0.767, respectively; comparable performance was observed in the validation cohort (C-index 0.677; 1-, 2-, and 3-year AUCs of 0.701, 0.717, and 0.832). Decision curve analysis indicated that the predictive performance of the model surpassed that of the China Liver Cancer (CNLC) and Barcelona Clinic Liver Cancer (BCLC) staging systems. Moreover, the high-risk group exhibited significantly poorer RFS compared with the low-risk group (all P < .001).
conclusionsThe proposed nomogram effectively stratifies postoperative recurrence risk and predicts RFS in overweight patients with HCC, providing a valuable tool for individualized prognostic assessment and clinical decision-making. However, due to its retrospective and single-center design, the findings require further validation in large-scale, multicenter studies across diverse populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.